Objective To explore the applicable method for the quantitative valuation of health economic loss by environmental pollution.Methods The contingent valuation method(CVM) and human capital method were respectively used to valuate the health economic loss by air pollution in Beijing and the comparison of the results was conducted.Results In 2005,the economic benefit of main air pollutants reduction by 50% in Beijing was 2.183 billion Yuan estimated by human capital method,and it was 10.891 billion Yuan estimated by CVM.The result of CVM is 4.99 times as high as that of human capital method.Conclusion CVM is a well recommended technique which can be used to estimate the total value of health loss by environment pollution,and this empirical study proved that it is feasible to estimated health economic loss in China.Further studies are needed to improve the efficiency of evaluation.

Environmental pollution could affect human health.The valuation on economic health loss due to environmental pollution could assist environment management to set more efficient environment policy.Contingent valuation method(CVM)is the worldwide used method to value loss caused by environmental pollution.CVM is a state preference non-market valuation method,which can flexibly assess the full economic value of public goods.CVM has been rarely used in environmental health loss valuation in China.Economic theory,application technique of CVM and it's potential bias was reviewed and discussed in this paper.Compared with the other methods,it could be concluded that CVM is a promising tool to value health loss by environment pollution in China.

Objective:To evaluate the effectiveness of Xipayi Mouth Rinse in the treatment of halitosis.Methods:PubMed/MEDLINE,China National Knowledge Infrastructure (CNKI) (1979-2015) and Weipu Database for Chinese Technical Periodicals (1989-2013) were systemically searched.The methodological quality of the included trials was assessed based on the Jadad scale and the available data were analyzed with RevMan software (version 5.3).Results:8 studies involving 608 participants satisfied the minimum criteria for Meta-analysis.The evidence showed that the Organoleptic Score (OS) of Xipayi Mouth Rinse compared with placebo for treatment of halitosis was [WMD =-0.43,95％ CI (-0.57,-0.29)],plaque index (PLI) [WMD =-1.59,95％ CI (-1.67,-1.51)];the OS of Xipayi Mouth Rinse compared with western medicine [WMD =0.16,95％ CI (0.05,0.28)],PLI [WMD =0.10,95％ CI(0.03,0.18)];the total efficiency of Xipayi Mouth Rinse compared with normal saline was[RR:1.64,95％ CI(1.11,2.42)].Conclusion:The current clinical evidence showed that the effectiveness of Xipayi Mouth Rinse in the treatment of halitosis is higher than the Placebo,but lower than western medicine.

The basic pathological change of diabetic macroangiopathy is atherosclerosis， and the metabolism legacy effect of hyperglycemia will cause continuous damage to the large vessels. Oxidative stress is a common mechanism for diabetes and its chronic complications and it is also the basis of the metabolism legacy effect which keeps damaging the large vessels. Anti-oxidant therapy can delay the course of diabetic macroangiopathy. According to the theory of traditional Chinese medicine （TCM）， the pathogenicity of hidden pathogen is concealing， lingering， and refractory. On the basis of the syndrome and treatment of collateral diseases， vessel-collateral theory， and hidden pathogen theory of TCM， the pathological changes of diabetic macroangiopathy are summarized as pathogen concealment-accumulation of sugar and lipids leading to phlegm and blood stasis-accumulation of toxins-damage to vessels and collaterals-hardening vessels. The core pathogenesis is the hidden pathogen damaging the collaterals， and the basic pathological change is vessel hardening. The toxins of sugar， lipid， phlegm， and stasis are the pathological products and the key to be treated. According to this theory， the medicinal materials with the functions of activating blood to dredging collaterals， resolving phlegm to clearing collaterals， Promoting qi to unblocking collaterals and removing toxins to shunting collaterals can be selected for prescription. These medicinal materials can inhibit the generation of reactive oxygen species， affect the oxidase activity， and enhance the antioxidant capacity， thereby regulating the oxidative stress response， protecting the vascular endothelial function， reducing the damage of the large blood vessels， and slowing down the progression of the disease. Such therapy is of great significance in clinical practice and research， providing a new idea for the prevention and treatment of diabetic macroangiopathy.

BACKGROUNDErtapenem has been demonstrated to be highly effective for the treatment of complicated infections. The aim of this study was to compare the efficacy and safety of ertapenem with ceftriaxone.

METHODSWe searched the PubMed, EMBASE, and the Cochrane Library for published randomized controlled trials (RCTs) that compared the efficacy and safety of ertapenem with ceftriaxone for the treatment of complicated infections including community-acquired pneumonia (CAP), complicated urinary tract infections (cUTIs), and complicated intra-abdominal infections (cIAIs). Meta-analysis was performed by RevMan 5.0.

RESULTSEight RCTs, involving 2 883 patients, were included in our meta-analysis. Ertapenem was associated with similar clinical treatment success with ceftriaxone for complicated infections (1 326 patients, fixed-effect model, OR: 1.13, 95% CI: 0.75-1.71). There was no difference between the compared treatment groups with regard to the microbiological treatment success, and no difference was found with regard to the incidence of clinical and laboratory drug-related adverse events between ertapenem and ceftriaxone groups. As to local tolerability, overall, there was no difference between the compared groups; however, in the subgroup analysis, local reaction was significantly less in the ertapenem subgroup than the ceftriaxone plus ceftriaxone subgroup.

CONCLUSIONSErtapenem can be used as effectively and safely as ceftriaxone for the treatment of complicated infections. It is an appealing option for the treatment of these complicated infections.

Anti-Bacterial Agents ; therapeutic use ; Ceftriaxone ; therapeutic use ; Humans ; Intraabdominal Infections ; drug therapy ; Pneumonia ; drug therapy ; Randomized Controlled Trials as Topic ; Urinary Tract Infections ; drug therapy ; beta-Lactams ; therapeutic use

The Coronavirus disease 2019 (COVID-19) has spread globally. Although mixed liver impairment has been reported in COVID-19 patients, the association of liver injury caused by specific subtype especially chronic hepatitis B (CHB) with COVID-19 has not been elucidated. In this multi-center, retrospective, and observational cohort study, 109 CHB and 327 non-CHB patients with COVID-19 were propensity score matched at an approximate ratio of 3:1 on the basis of age, sex, and comorbidities. Demographic characteristics, laboratory examinations, disease severity, and clinical outcomes were compared. Furthermore, univariable and multivariable logistic and Cox regression models were used to explore the risk factors for disease severity and mortality, respectively. A higher proportion of CHB patients (30 of 109 (27.52%)) developed into severe status than non-CHB patients (17 of 327 (5.20%)). In addition to previously reported liver impairment markers, such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin, we identified several novel risk factors including elevated lactate dehydrogenase (⩾ 245 U/L, hazard ratio (HR) = 8.639, 95% confidence interval (CI) = 2.528-29.523; P < 0.001) and coagulation-related biomarker D-dimer (⩾ 0.5 µg/mL, HR = 4.321, 95% CI = 1.443-12.939; P = 0.009) and decreased albumin (< 35 g/L, HR = 0.131, 95% CI = 0.048-0.361; P < 0.001) and albumin/globulin ratio (< 1.5, HR = 0.123, 95% CI = 0.017-0.918; P = 0.041). In conclusion, COVID-19 patients with CHB were more likely to develop into severe illness and die. The risk factors that we identified may be helpful for early clinical surveillance of critical progression.
COVID-19 ; Cohort Studies ; Hepatitis B, Chronic/epidemiology* ; Humans ; Retrospective Studies ; Risk Factors